These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 21187595)

  • 1. [Odanacatib (MK-0822)].
    Nagase Y; Tanaka S
    Clin Calcium; 2011 Jan; 21(1):59-62. PubMed ID: 21187595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Reducing bone resorption by cathepsin K inhibitor and treatment of osteoporosis].
    Watanabe R; Okazaki R
    Clin Calcium; 2014 Jan; 24(1):59-67. PubMed ID: 24369281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Odanacatib, a cathepsin K inhibitor for the treatment of osteoporosis and other skeletal disorders associated with excessive bone remodeling.
    Lewiecki EM
    IDrugs; 2009 Dec; 12(12):799-809. PubMed ID: 19943223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Odanacatib for the treatment of osteoporosis.
    Boggild MK; Gajic-Veljanoski O; McDonald-Blumer H; Ridout R; Tile L; Josse R; Cheung AM
    Expert Opin Pharmacother; 2015; 16(11):1717-26. PubMed ID: 26149759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [New approach for osteoporosis treatment: cathepsin K inhibitor, ONO-5334].
    Manako J
    Clin Calcium; 2011 Jan; 21(1):64-9. PubMed ID: 21187596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density.
    Bone HG; McClung MR; Roux C; Recker RR; Eisman JA; Verbruggen N; Hustad CM; DaSilva C; Santora AC; Ince BA
    J Bone Miner Res; 2010 May; 25(5):937-47. PubMed ID: 19874198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and translational pharmacology of the cathepsin K inhibitor odanacatib studied for osteoporosis.
    Stone JA; McCrea JB; Witter R; Zajic S; Stoch SA
    Br J Clin Pharmacol; 2019 Jun; 85(6):1072-1083. PubMed ID: 30663085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The resorptive apparatus of osteoclasts supports lysosomotropism and increases potency of basic versus non-basic inhibitors of cathepsin K.
    Fuller K; Lindstrom E; Edlund M; Henderson I; Grabowska U; Szewczyk KA; Moss R; Samuelsson B; Chambers TJ
    Bone; 2010 May; 46(5):1400-7. PubMed ID: 20097319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological inhibition of cathepsin K: A promising novel approach for postmenopausal osteoporosis therapy.
    Mukherjee K; Chattopadhyay N
    Biochem Pharmacol; 2016 Oct; 117():10-9. PubMed ID: 27106079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Mild Inhibition of Cathepsin K Paradoxically Stimulates the Resorptive Activity of Osteoclasts in Culture.
    Pirapaharan DC; Søe K; Panwar P; Madsen JS; Bergmann ML; Overgaard M; Brömme D; Delaisse JM
    Calcif Tissue Int; 2019 Jan; 104(1):92-101. PubMed ID: 30194476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of cathepsin K for treatment of osteoporosis.
    Boonen S; Rosenberg E; Claessens F; Vanderschueren D; Papapoulos S
    Curr Osteoporos Rep; 2012 Mar; 10(1):73-9. PubMed ID: 22228398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of bone resorption by the cathepsin K inhibitor odanacatib is fully reversible.
    Zhuo Y; Gauthier JY; Black WC; Percival MD; Duong LT
    Bone; 2014 Oct; 67():269-80. PubMed ID: 25038310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent developments in cathepsin K inhibitor design.
    Grabowskal U; Chambers TJ; Shiroo M
    Curr Opin Drug Discov Devel; 2005 Sep; 8(5):619-30. PubMed ID: 16159024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential role of odanacatib in the treatment of osteoporosis.
    Ng KW
    Clin Interv Aging; 2012; 7():235-47. PubMed ID: 22866001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An orally active cathepsin K inhibitor, furan-2-carboxylic acid, 1-{1-[4-fluoro-2-(2-oxo-pyrrolidin-1-yl)-phenyl]-3-oxo-piperidin-4-ylcarbamoyl}-cyclohexyl)-amide (OST-4077), inhibits osteoclast activity in vitro and bone loss in ovariectomized rats.
    Kim MK; Kim HD; Park JH; Lim JI; Yang JS; Kwak WY; Sung SY; Kim HJ; Kim SH; Lee CH; Shim JY; Bae MH; Shin YA; Huh Y; Han TD; Chong W; Choi H; Ahn BN; Yang SO; Son MH
    J Pharmacol Exp Ther; 2006 Aug; 318(2):555-62. PubMed ID: 16699068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cathepsin K antagonists: preclinical and clinical data].
    Gamsjäger M; Resch H
    Wien Med Wochenschr; 2015 Feb; 165(3-4):65-70. PubMed ID: 25572547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cathepsin K Inhibition: A New Mechanism for the Treatment of Osteoporosis.
    Duong le T; Leung AT; Langdahl B
    Calcif Tissue Int; 2016 Apr; 98(4):381-97. PubMed ID: 26335104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled phase I studies.
    Stoch SA; Zajic S; Stone J; Miller DL; Van Dyck K; Gutierrez MJ; De Decker M; Liu L; Liu Q; Scott BB; Panebianco D; Jin B; Duong LT; Gottesdiener K; Wagner JA
    Clin Pharmacol Ther; 2009 Aug; 86(2):175-82. PubMed ID: 19421185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate.
    Stroup GB; Lark MW; Veber DF; Bhattacharyya A; Blake S; Dare LC; Erhard KF; Hoffman SJ; James IE; Marquis RW; Ru Y; Vasko-Moser JA; Smith BR; Tomaszek T; Gowen M
    J Bone Miner Res; 2001 Oct; 16(10):1739-46. PubMed ID: 11585335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of the cathepsin K inhibitor odanacatib on osteoclastic bone resorption and vesicular trafficking.
    Leung P; Pickarski M; Zhuo Y; Masarachia PJ; Duong LT
    Bone; 2011 Oct; 49(4):623-35. PubMed ID: 21718816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.